Cryosurgical Ablation and Radiofrequency Ablation for Unresectable Hepatic Malignant Neoplasms

Abstract

Some say the world will end in fire, Some say in ice. From what I've tasted of desire I hold with those who favor fire. But if it had to perish twice, I think I know enough of hate To know that for destruction ice Is also great And would suffice.

Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma

“…28 It is difficult to compare the results of cryotherapy and radiofrequency ablation because of the lack of standard criteria for defining resectability and the different histologic types reported in most series. One study comparing the two techniques 29 demonstrated that radiofrequency ablation resulted in lower morbidity for tumors less than 3 cm in diameter, but was less effective than cryotherapy for treating larger tumors. In this subgroup of large tumors, cryotherapy involved significantly shorter treatment time and lower rates of complications and local disease recurrence.…”

Replay

“…3,4 It was a well-designed first randomized trial that reports on these potential benefits, which is consistent with previous nonrandomized studies. 5,6 However, the subgroup analyses are still losing their statistical power owing to the small number of patients, which is sensitively influenced by aberrant cases. Additional information, including baseline characteristics and 1-, 3-, and 5-year progression free survival (adjusted by multivariate regression model, if necessary) for each of the >3 cm HCC patient subgroups would be required to reduce perceived bias.…”

Randomized, controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma

“…3,4 It was a well-designed first randomized trial that reports on these potential benefits, which is consistent with previous nonrandomized studies. 5,6 However, the subgroup analyses are still losing their statistical power owing to the small number of patients, which is sensitively influenced by aberrant cases. Additional information, including baseline characteristics and 1-, 3-, and 5-year progression free survival (adjusted by multivariate regression model, if necessary) for each of the >3 cm HCC patient subgroups would be required to reduce perceived bias.…”